Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic demyelinating polyneuropathy of autoimmune origin with a progressive or relapsing course. Diagnosis is based on clinical presentation and electrophysiological findings in accordance with the EFNS/PNS consensus guidelines. IVIg is the first line treatment witch has been shown to be effective in several placebo-controlled trials. Once IVIg therapy produces a response and is well tolerated, some patients are able to continue their treatment in the home setting. The HOME LINK system offers an integrated, global solution based on telemonitoring technology providing continuous, remote monitoring of Privigen® infusions administered at home.
Study Type
OBSERVATIONAL
Enrollment
11
Telemonitoring system which include web platform and connected devices.
Hôpital Pellegrin, Bordeaux University Hospital (CHU)
Bordeaux, France
Hôpital Henri Mondor - APHP
Créteil, France
Hôpital Roger Salengro - CHRU
Lille, France
Hôpital Pierre Wertheimer - HCL
Lyon, France
Hôpital La Timone - APHM
Marseille, France
Hôpital Gui de Chauliac - Montpellier University Hospital (CHU)
Montpellier, France
Hôpital Pasteur 2 - Nice University Hospital (CHU)
Nice, France
Hôpital La Pitié-Salpêtrière - APHP
Paris, France
Hôpital Lariboisière - APHP
Paris, France
Hôpital Nord - Saint Etienne University Hospital (CHU)
Saint-Etienne, France
Evaluate HOME LINK telemonitoring system for patients receiving home-based IVIg therapy
The conventional method of home monitoring requires using a visiting nurse. HOME LINK is a telemonitoring system that is an alternative to this conventional method offering remote at-home monitoring. HOME LINK monitors the patient's health parameters from home. In this way it enables an adjustment of the infusion conditions or intervention of a qualified healthcare professional in the event of an incident. Home Link will be evaluated for failure rate of connection to the telemonitoring platform, failure rate of transmission of self-measurements to the telemonitoring platform, failure rate of transmission of documents relating to home-based treatment, and failure rate of contacting one of the healthcare professionals involved in patient care during the at-home infusions.
Time frame: 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.